RU2006127467A - INHALATION PREPARATION FORM CONTAINING SIMPLE SULFALKYL ETHER-CYCLODEXTRIN AND CORTICOSTEROID - Google Patents

INHALATION PREPARATION FORM CONTAINING SIMPLE SULFALKYL ETHER-CYCLODEXTRIN AND CORTICOSTEROID Download PDF

Info

Publication number
RU2006127467A
RU2006127467A RU2006127467/15A RU2006127467A RU2006127467A RU 2006127467 A RU2006127467 A RU 2006127467A RU 2006127467/15 A RU2006127467/15 A RU 2006127467/15A RU 2006127467 A RU2006127467 A RU 2006127467A RU 2006127467 A RU2006127467 A RU 2006127467A
Authority
RU
Russia
Prior art keywords
amino
composition according
hydroxy
methyl
corticosteroid
Prior art date
Application number
RU2006127467/15A
Other languages
Russian (ru)
Other versions
RU2390330C2 (en
Inventor
Джеймс Д. ПИПКИН (US)
Джеймс Д. Пипкин
Руперт О. ЦИММЕРЕР (US)
Руперт О. ЦИММЕРЕР
Дайан О. ТОМПСОН (US)
Дайан О. ТОМПСОН
Джерольд Л. МОШЕР (US)
Джерольд Л. МОШЕР
Original Assignee
Сайдекс, Инк. (Us)
Сайдекс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сайдекс, Инк. (Us), Сайдекс, Инк. filed Critical Сайдекс, Инк. (Us)
Publication of RU2006127467A publication Critical patent/RU2006127467A/en
Application granted granted Critical
Publication of RU2390330C2 publication Critical patent/RU2390330C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Claims (23)

1. Ингаляционная композиция, включающая SAE-γ-CD, этерифицированный или неэтерифицированный кортикостероид, и водную жидкую среду, где SAE-γ-CD присутствует в количестве, достаточном для растворения существенной части кортикостероида.1. An inhalation composition comprising SAE-γ-CD, an esterified or non-esterified corticosteroid, and an aqueous liquid medium, where SAE-γ-CD is present in an amount sufficient to dissolve a substantial portion of the corticosteroid. 2. Композиция по п.1, дополнительно включающая одно или более терапевтических средств, независимо выбранных в каждом случае из группы, состоящей из агониста В2 адренорецепторов, агониста допаминовых (D2) рецепторов, местного анестетика, антихолинергического средства, ингибитора IL-5, антисмыслового модулятора IL-5, милринона (1,6-дигидро-2-метил-6-оксо-[3,4'-бипиридин]-5-карбонитрила); милринона лактата; ингибитора триптазы; антагониста рецепторов тахикинина; антагониста рецепторов лейкотриена; ингибитора 5-липоксигеназы и анти-IgE антитела.2. The composition according to claim 1, further comprising one or more therapeutic agents, independently selected in each case from the group consisting of a B 2 adrenergic receptor agonist, a dopamine (D 2 ) receptor agonist, a local anesthetic, an anticholinergic agent, an IL-5 inhibitor, the antisense modulator of IL-5, milrinone (1,6-dihydro-2-methyl-6-oxo- [3,4'-bipyridine] -5-carbonitrile); milrinone lactate; tryptase inhibitor; tachykinin receptor antagonist; leukotriene receptor antagonist; 5-lipoxygenase inhibitor and anti-IgE antibodies. 3. Композиция по п.2, где агонист В2 адренорецепторов выбран из группы, состоящей из албутерола (альфа1-(((1,1-диметилэтил)амино)метил)-4-гидрокси-1,3-бензолдиметанола); бамбутерола (сложного 5-(2-((1,1-диметилэтил)амино)-1-гидроксиэтил)-1,3-фениленового эфира диметилкарбаминовой кислоты; битолтерола (сложного 4-(2-((1,1-диметилэтил)амино-1-гидроксиэтил)-1,2-фениленового эфира 4-метилбензойной кислоты; броксатерола (3-бром-альфа-(((1,1-диметилэтил)амино)метил)-5-изоксазолметанола); изопротеренола (4-(1-гидрокси-2-((1-метилэтил)амино)этил)-1,2-бензолдиола; триметохинола (1,2,3,4-тетрагидро-1-((3,4,5-триметоксифенил)метил)-6,7-изохинолиндиола); кленбутерола (4-амино-3,5-дихлор-альфа-(((1,1-диметилэтил)амино)метил)бензолметанола); фенотерола (5-(1-гидрокси-2-((2-4(4-гидроксифенил)-1-метилэтил)амино)этил)-1,3-бензолдиола); формотерола (2-гидрокси-5-((1RS)-1-гидрокси-2-(((1RS)-2-(п-метоксифенил)-1-метилэтил)амино)этил)форманилида); (R,R)-формотерола; десформотерола ((R,R) или (S,S)-3-амино-4-гидрокси-альфа-(((2-(4-метоксифенил)-1-метилэтил)амино)метил)бензолметанола); гексопреналина (4,4′-(1,6-гександиил)-бис(имино(1-гидрокси-2,1-этандиил)))бис-1,2-бензолдиола); изоэтарина (4-(1-гидрокси-2-((1-метилэтил)амино)бутил)-1,2-бензолдиола); изопреналина (4-(1-гидрокси-2-((1-метилэтил)амино)этил)-1,2-бензолдиола); мета-протеренола (5-(1-гидрокси-2-((1-метилэтил)амино)этил)-1,3-бензолдиола); пикуметерола (4-амино-3,5-дихлор-альфа-(((6-(2-(2-пиридинил)этокси)гексил)амино)метил)бензолметанола); пирбутерола (α6-(((1,1-диметилэтил)амино)метил)-3-гидрокси-2,6-пиридинметанола); прокатерола (((R*,S*)-(+/-)-8-гидрокси-5-(1-гидрокси-2-((1-метилэтил)амино)бутил)-2(1Н)-хинолинона); репротерола ((7-(3-((2-(3,5-дигидрофенил)-2-гидроксиэтил)амино)пропил)-3,7-дигидро-1,3-диметил-1Н-пурин-2,6-диона); римитерола (4-(гидрокси-2-пиперидинилметил)-1,2-бензолдиола); сальбутамола ((+/-)-альфа1-(((1,1-диметилэтил)амино)метил)-4-гидрокси-1,3-бензолдиметанола); (R)-сальбутамола; сальметерола ((+/-)-4-гидрокси-альфа1-(((6-(4-фенилбутокси)гексил)амино)метил)-1,3-бензолдиметанола); (R)-сальметерола; тербуталина (5-(2-((1,1-диметилэтил)амино)-1-гидроксиэтил)-1,3-бензолдиола); тулобутерола (2-хлор-альфа-(((1,1-диметилэтил)амино)метил)бензолметанола); и ТА-2005 (8-гидрокси-5-((1R)-1-гидрокси-2-(N-((1R)-2-(4-метоксифенил)-1-метилэтил)амино)этил)карбостирилгидрохлорида).3. The composition according to claim 2, where the B 2 adrenergic agonist is selected from the group consisting of albuterol (alpha 1 - (((1,1-dimethylethyl) amino) methyl) -4-hydroxy-1,3-benzenedimethanol); bambuterol (5- (2 - ((1,1-dimethylethyl) amino) -1-hydroxyethyl) -1,3-phenylene dimethylcarbamic acid ester; bitolterol (4- (2 - ((1,1-dimethylethyl) amino 4-methylbenzoic acid -1-hydroxyethyl) -1,2-phenylene ester; broxaterol (3-bromo-alpha - (((1,1-dimethylethyl) amino) methyl) -5-isoxazolemethanol); isoproterenol (4- (1 -hydroxy-2 - ((1-methylethyl) amino) ethyl) -1,2-benzenediol; trimethoquinol (1,2,3,4-tetrahydro-1 - ((3,4,5-trimethoxyphenyl) methyl) -6 , 7-isoquinolinediol); Clenbuterol (4-amino-3,5-dichloro-alpha - (((1,1-dimethylethyl) amino) methyl) benzenemethanol); phenoterol (5- (1 -hydroxy-2 - ((2-4 (4-hydroxyphenyl) -1-methylethyl) amino) ethyl) -1,3-benzenediol); formoterol (2-hydroxy-5 - ((1RS) -1-hydroxy-2 - (((1RS) -2- (p-methoxyphenyl) -1-methylethyl) amino) ethyl) formanilide); (R, R) -formoterol; desformoterol ((R, R) or (S, S) -3- amino-4-hydroxy-alpha - (((2- (4-methoxyphenyl) -1-methylethyl) amino) methyl) benzenemethanol); hexoprenaline (4,4 ′ - (1,6-hexanediyl) bis (imino (1 -hydroxy-2,1-ethanediyl))) bis-1,2-benzenediol); isoetharin (4- (1-hydroxy-2 - ((1-methylethyl) amino) butyl) -1,2-benzenediol); isoprenaline (4- (1-hydroxy-2 - ((1-methylethyl) amino) ethyl) -1,2-benzenediol); meta-proterenol (5- (1-hydroxy-2 - ((1-methylethyl) amino) ethyl) -1,3-benzenediol); picumeterol (4-amino-3,5-dichloro-alpha - (((6- (2- (2-pyridinyl) ethoxy) hexyl) amino) methyl) benzenemethanol); pirbuterol (α 6 - (((1,1-dimethylethyl) amino) methyl) -3-hydroxy-2,6-pyridinomethanol); roterol ((((R *, S *) - (+/-) - 8-hydroxy-5- (1-hydroxy-2 - ((1-methylethyl) amino) butyl) -2 (1H) -quinolinone); reproterol ((7- (3 - ((2- (3,5-dihydrophenyl) -2-hydroxyethyl) amino) propyl) -3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione) ; rimeterol (4- (hydroxy-2-piperidinylmethyl) -1,2-benzenediol); salbutamol ((+/-) - alpha 1 - (((1,1-dimethylethyl) amino) methyl) -4-hydroxy-1 , 3-benzenedimethanol); (R) -salbutamol; salmeterol ((+/-) - 4-hydroxy-alpha 1 - (((6- (4-phenylbutoxy) hexyl) amino) methyl) -1,3-benzenedimethanol) ; (R) -salmeterol; terbutaline (5- (2 - ((1,1-dimethylethyl) amino) -1-hydroxyethyl) -1,3-benzenediol); tulobuterol (2 op-alpha - ((((1,1-dimethylethyl) amino) methyl) benzenemethanol); and TA-2005 (8-hydroxy-5 - ((1R) -1-hydroxy-2- (N - ((1R) - 2- (4-methoxyphenyl) -1-methylethyl) amino) ethyl) carbostyryl hydrochloride). 4. Композиция по п.2, где агонист допаминовых (D2) рецепторов выбран из группы, состоящей из апоморфина ((r)-5,6,6а,7-тетрагидро-6-метил-4Н-дибензо[de,gl]хинолин-10,11-диола); бромкриптина ((5′-α)-2-бром-12′-гидрокси-2′-(1-метилэтил)-5′-(2-метилпропил)эрготаман-3′,6′,18-триона); каберголина ((8β)-N-(3-(диметиламино)пропил)-N-((этиламино)карбонил)-6-(2-пропенил)эрголин-8-карбоксамида); лизурида (N′-((8-альфа)-9,10-дидегидро-6-метилэрголин-8-ил)-N,N-диэтилмочевины); перголида ((8-бета)-8-((метилтио)метил)-6-пропилэрголина); леводопы (3-гидрокси-L-тирозина); прамипексола ((s)-4,5,6,7-тетрагидро-N6-пропил-2,6-бензотиазолдиамина); хинпиролгидрохлорида (транс-(-)-4аR-4,4a,5,6,7,8,8a,9-октагидро-5-пропил-1Н-пиразол[3,4-g]хинолингидрохлорида); ропинирола (4-(2-(дипропиламино)этил)-1,3-дигидро-2Н-индол-2-она); и талипексола (5,6,7,8-тетрагидро-6-(2-пропенил)-4Н-тиазол[4,5-d]азепин-2-амина).4. The composition according to claim 2, where the dopamine (D 2 ) receptor agonist is selected from the group consisting of ((r) -5,6,6a, 7-tetrahydro-6-methyl-4H-dibenzo [de, gl] apomorphine quinoline-10,11-diol); bromocriptine ((5′-α) -2-bromo-12′-hydroxy-2 ′ - (1-methylethyl) -5 ′ - (2-methylpropyl) ergotamine-3 ′, 6 ′, 18-trion); cabergoline ((8β) -N- (3- (dimethylamino) propyl) -N - ((ethylamino) carbonyl) -6- (2-propenyl) ergoline-8-carboxamide); lysuride (N ′ - ((8-alpha) -9,10-didehydro-6-methylergolin-8-yl) -N, N-diethylurea); pergolide ((8-beta) -8 - ((methylthio) methyl) -6-propylene ergoline); levodopa (3-hydroxy-L-tyrosine); pramipexole ((s) -4,5,6,7-tetrahydro-N 6 -propyl-2,6-benzothiazoldiamine); quinopyrol hydrochloride (trans - (-) - 4aR-4,4a, 5,6,7,8,8a, 9-octahydro-5-propyl-1H-pyrazole [3,4-g] quinoline hydrochloride); ropinirole (4- (2- (dipropylamino) ethyl) -1,3-dihydro-2H-indol-2-one); and thalipexole (5,6,7,8-tetrahydro-6- (2-propenyl) -4H-thiazole [4,5-d] azepin-2-amine). 5. Композиция по п.2, где антихолинергический агент выбран из группы, состоящей из ипратропия бромида, окситропия бромида, атропина метилнитрата, атропина сульфата, ипратропия, экстракта красавки, скополамина, скополамина метобромида, гоматропина метобромида, гиосциамина, изоприопрамида, орфенадрина, бензалкония хлорида, титропия бромида и гликопиррония бромида.5. The composition according to claim 2, where the anticholinergic agent is selected from the group consisting of ipratropium bromide, oxytropium bromide, atropine methyl nitrate, atropine sulfate, ipratropium, belladonna extract, scopolamine, scopolamine metobromide, homatropine metobromide, hyoscyamine, orosonaprioprine, isoprioprine, isoprioprine, isoprioprine titropium bromide and glycopyrronium bromide. 6. Композиция по п.1, где местный анестетик выбран из группы, состоящей из лидокаина, N-ариламида, аминалкилбензоата, прилокаина и этидокаина.6. The composition according to claim 1, where the local anesthetic is selected from the group consisting of lidocaine, N-arylamide, aminalkylbenzoate, prilocaine and ethidocaine. 7. Композиция по п.1, где кортикостероид выбран из группы, состоящей из альдостерона, беклометазона, бетаметазона, буденозида, циклезонида, клопреднола, кортизона, кортивазола, деоксикортона, дезонида, дезоксиметазона, дексаметазона, дифторкортолона, флукролорона, флуметазона, флунизолида, флуоцинолона, флуоцинонида, флуокортинбутила, фторкортизона, фторкортолона, фторметолона, флурандренолона, флутиказона, гальцинонида, гидрокортизона, икометазона, мепреднизона, метилпреднизолона, мометазона, параметазона, преднизолона, преднизона, рофлепонида, RPR 106541, тиксокортола, триамцинолона и их соответствующих фармацевтически приемлемых производных.7. The composition according to claim 1, where the corticosteroid is selected from the group consisting of aldosterone, beclomethasone, betamethasone, budenoside, cyclesenide, cloprednol, cortisone, cortivazole, deoxycortone, desonide, deoxymethasone, dexamethasone, difluorocortolone, fluconolonone, fluconolonone, fluconolonone, fluconolonone, fluconolonone, fluconolonone, fluconolonone, fluconolonone, fluconolonone, fluconolonone, fluconolonone, fluololonone, fluolazolone, flucololone, fluocinonide, fluocortinbutyl, fluorocortisone, fluorocortolone, fluorometholone, flurandrenolone, fluticasone, galcinonide, hydrocortisone, icomethasone, meprednisone, methylprednisolone, mometasone, parametasone, prednisolone, prednisone leponida, RPR 106541, tixocortol, triamcinolone, and their respective pharmaceutically acceptable derivatives. 8. Композиция по п.7, где производное кортикостероида выбрано из группы, состоящей из беклометазона дипропионата, беклометазона монопропионата, дексаметазона 21-изоникотината, флутиказона пропионата, икометазона энбутата, тиксокортола 21-пивалата и триамцинолонацетонида.8. The composition of claim 7, wherein the corticosteroid derivative is selected from the group consisting of beclomethasone dipropionate, beclomethasone monopropionate, dexamethasone 21-isonicotinate, fluticasone propionate, icomethasone enbutate, thixocortol 21-pivalate and triamcinolone. 9. Композиция по п.1, где кортикостероид выбран из группы, состоящей из беклометазона дипропионата, буденозида, флунизолида, флутиказона пропионата, мометазона фуроата и триамцинолонацетонида.9. The composition according to claim 1, where the corticosteroid is selected from the group consisting of beclomethasone dipropionate, budenoside, flunisolide, fluticasone propionate, mometasone furoate and triamcinolone acetonide. 10. Композиция по п.1, где SAE-γ-CD присутствует в количестве, достаточном для солюбилизации, по меньшей мере, 90% кортикостероида.10. The composition according to claim 1, where SAE-γ-CD is present in an amount sufficient to solubilize at least 90% of the corticosteroid. 11. Композиция по п.1, где SAE-γ-CD присутствует в количестве, достаточном для солюбилизации, по меньшей мере, 95% кортикостероида.11. The composition according to claim 1, where SAE-γ-CD is present in an amount sufficient to solubilize at least 95% of the corticosteroid. 12. Композиция по п.11, где SAE-γ-CD присутствует в количестве, достаточном для солюбилизации достаточного количества кортикостероида, так что препаративная форма в виде раствора представляет собой, по существу, прозрачный раствор, содержащий менее чем 5 мас.% твердого кортикостероида.12. The composition according to claim 11, where the SAE-γ-CD is present in an amount sufficient to solubilize a sufficient amount of corticosteroid, so that the formulation in the form of a solution is a substantially transparent solution containing less than 5 wt.% Solid corticosteroid . 13. Композиция по п.1, в которой молярное отношение кортикостероида к SAE-CD находится в диапазоне от примерно 1:2 до примерно 1:10000.13. The composition according to claim 1, in which the molar ratio of corticosteroid to SAE-CD is in the range from about 1: 2 to about 1: 10000. 14. Композиция по п.1, где препаративная форма в виде раствора, кроме того, включает обычный консервант, антиоксидант, буферный агент, подкисляющий агент, солюбилизирующий агент, красящее вещество, агент, усиливающий комплексообразование, солевой раствор, электролит, другое терапевтическое средство, подщелачивающий агент, модификатор тоничности, модификатор поверхностного натяжения, модификатор вязкости, модификатор плотности, модификатор летучести, противовспенивающий агент, отдушку, подслащивающий агент, гидрофильный полимер или их комбинацию.14. The composition according to claim 1, where the preparative form in the form of a solution, in addition, includes a conventional preservative, antioxidant, a buffering agent, an acidifying agent, a solubilizing agent, a coloring agent, a complexation enhancing agent, saline solution, electrolyte, another therapeutic agent, alkalizing agent, tonicity modifier, surface tension modifier, viscosity modifier, density modifier, volatility modifier, anti-foaming agent, fragrance, sweetening agent, hydrophilic polymer or their mbinatsiyu. 15. Композиция по п.1, где препаративная форма в виде раствора имеет срок хранения, по меньшей мере, 6 мес.15. The composition according to claim 1, where the formulation in the form of a solution has a shelf life of at least 6 months. 16. Композиция по п.1, дополнительно включающая жидкий носитель, отличный от воды.16. The composition according to claim 1, further comprising a liquid carrier other than water. 17. Композиция по п.1, где препаративная форма включает менее или примерно 21,5%±5% масс./масс. SAE-CD.17. The composition according to claim 1, where the preparative form includes less than or about 21.5% ± 5% wt./mass. SAE-CD. 18. Композиция по п.1, где препаративная форма включает менее или примерно 30%±5% масс./масс. SAE-CD.18. The composition according to claim 1, where the preparative form includes less than or about 30% ± 5% wt./mass. SAE-CD. 19. Композиция по п.1, где SAE-CD присутствует в количестве, достаточном для растворения, по меньшей мере, 50 мас.% кортикостероида.19. The composition according to claim 1, where the SAE-CD is present in an amount sufficient to dissolve at least 50 wt.% Corticosteroid. 20. Композиция по п.1, где SAE-CD присутствует в жидкой препаративной форме в концентрации от примерно 10 до примерно 500 мг SAE-CD на 1 мл жидкой препаративной формы.20. The composition according to claim 1, where SAE-CD is present in a liquid formulation in a concentration of from about 10 to about 500 mg of SAE-CD per 1 ml of liquid formulation. 21. Композиция по любому из указанных выше пунктов, где циклодекстрин представляет собой соединение формулы I21. The composition according to any one of the above paragraphs, where the cyclodextrin is a compound of formula I
Figure 00000001
Figure 00000001
 где n=6;where n = 6; каждый R1, R2, R3, R4, R5, R6, R7, R8, и R9 независимо представляет собой -О- или группу -O-(C2-C6алкилен)-SO3 -, где, по меньшей мере, один из R1-R9 независимо представляет собой группу -O-(CH2)mSO3 -, где m=2-6, -OCH2CH2CH2SO3 - или -OCH2CH2CH2CH2SO3 -); иeach R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 independently represents —O— or a group —O— (C 2 -C 6 alkylene) —SO 3 - , where at least one of R 1 -R 9 independently represents a group -O- (CH 2 ) m SO 3 - , where m = 2-6, -OCH 2 CH 2 CH 2 SO 3 - or - OCH 2 CH 2 CH 2 CH 2 SO 3 - ); and каждый S1, S2, S3, S4, S5, S6, S7, S8, и S9 независимо представляет собой фармацевтически приемлемый катион.each S 1 , S 2 , S 3 , S 4 , S 5 , S 6 , S 7 , S 8 , and S 9 independently represents a pharmaceutically acceptable cation. 22. Композиция по любому из пп.1-20, где циклодекстрин представляет собой соединение формулы II (SAEz-γ-CD), где "z" имеет диапазон от 1 до 24, и где "SAE" представляет сульфоалкилэфирный заместитель, и величина "z" представляет среднюю степень замещения молекулы CD сульфоалкилэфирными группами.22. The composition according to any one of claims 1 to 20, where the cyclodextrin is a compound of formula II (SAEz-γ-CD), where "z" has a range from 1 to 24, and where "SAE" is a sulfoalkyl ether substituent, and the value " z "represents the average degree of substitution of the CD molecule by sulfoalkyl ether groups. 23. Композиция по п.22, где циклодекстрин выбран из группы, состоящей из23. The composition according to item 22, where the cyclodextrin is selected from the group consisting of SAEz-γ-CDSAEz-γ-CD SEEz-γ-CDSEEz-γ-CD SPEz-γ-CDSPEz-γ-CD SBEz-γ-CDSBEz-γ-CD SptEz-γ-CDSptEz-γ-CD SHEz-γ-CD.SHEz-γ-CD.
RU2006127467/15A 2003-12-31 2004-12-31 Inhalation formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid RU2390330C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53362803P 2003-12-31 2003-12-31
US60/533,628 2003-12-31

Publications (2)

Publication Number Publication Date
RU2006127467A true RU2006127467A (en) 2008-02-10
RU2390330C2 RU2390330C2 (en) 2010-05-27

Family

ID=34794240

Family Applications (3)

Application Number Title Priority Date Filing Date
RU2006127443/15A RU2388462C2 (en) 2003-12-31 2004-12-31 Inhalation composition containing sulfoalkyl ether
RU2006127432/15A RU2006127432A (en) 2003-12-31 2004-12-31 INHALATION COMPOSITION CONTAINING SULFALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID OBTAINED FROM THE UNIT DOSAGE OF SUSPENSION
RU2006127467/15A RU2390330C2 (en) 2003-12-31 2004-12-31 Inhalation formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid

Family Applications Before (2)

Application Number Title Priority Date Filing Date
RU2006127443/15A RU2388462C2 (en) 2003-12-31 2004-12-31 Inhalation composition containing sulfoalkyl ether
RU2006127432/15A RU2006127432A (en) 2003-12-31 2004-12-31 INHALATION COMPOSITION CONTAINING SULFALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID OBTAINED FROM THE UNIT DOSAGE OF SUSPENSION

Country Status (15)

Country Link
EP (4) EP1729724A4 (en)
JP (6) JP2007517069A (en)
KR (3) KR20070005586A (en)
CN (3) CN1921834A (en)
AU (3) AU2004312095A1 (en)
BR (3) BRPI0418386A (en)
CA (3) CA2551826A1 (en)
DK (1) DK1732512T3 (en)
HU (1) HUE032527T2 (en)
IL (6) IL176576A0 (en)
MX (2) MXPA06007581A (en)
NZ (1) NZ548225A (en)
PT (1) PT1732512T (en)
RU (3) RU2388462C2 (en)
WO (3) WO2005065649A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2591804C2 (en) * 2009-02-25 2016-07-20 Супратек Фарма, Инк. Compositions of bendamustine and cyclopolysaccharide

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
JP2007534693A (en) 2004-04-23 2007-11-29 サイデックス・インコーポレイテッド DPI formulation containing sulfoalkyl ether cyclodextrin
DE102005041860A1 (en) * 2005-09-02 2007-03-08 Schering Ag Nano-particle embedded- and charged-complex, useful for the production of a pharmaceutical composition, comprises two complex partners, where the complex partner is an embedded anionic and a cationic active substance
PT2335707E (en) * 2005-10-26 2015-09-10 Cydex Pharmaceuticals Inc Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
CN105237621A (en) 2005-11-09 2016-01-13 欧尼斯治疗公司 Compounds for enzyme inhibition
CN101309707A (en) * 2005-11-15 2008-11-19 巴克斯特国际公司 Compositions comprising lipoxygenase inhibitors and cyclodextrin
AU2006327566A1 (en) * 2005-12-02 2007-06-28 Alembic Limited Stabilized pharmaceutical composition of pramipexole and method of preparation thereof
WO2007075800A2 (en) * 2005-12-20 2007-07-05 Tika Läkemedel Ab Methods and systems for the delivery of corticosteroids
ES2389231T3 (en) * 2005-12-21 2012-10-24 Meda Pharma Gmbh & Co. Kg Combination of anticholinergics, glucocorticoids and beta2 agonists for the treatment of inflammatory diseases
MX2008010222A (en) * 2006-02-10 2008-10-17 Pari Pharma Gmbh Nebulised antibiotics for inhalation therapy.
JP2009526619A (en) * 2006-02-15 2009-07-23 ティカ レーケメデル アーベー Sterilization of corticosteroids with weight loss
NZ571537A (en) * 2006-04-03 2012-06-29 Nutramax Lab Inc Stabilized pentosan polysulfate (PPS) formulations and methods of analayzing them
EP2041158B1 (en) 2006-06-19 2013-04-17 Onyx Therapeutics, Inc. Peptide epoxyketones for proteasome inhibition
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
EP1894559A1 (en) * 2006-09-01 2008-03-05 PARI Pharma GmbH Means to solubilise steroids for inhalation
WO2008047149A1 (en) * 2006-10-19 2008-04-24 Cipla Limited Pharmaceutical compositions and nasal spray incorporating anhydrous mometasone furoate
WO2008065142A1 (en) * 2006-11-29 2008-06-05 N.V. Organon Stabilized solution of rocuronium comprising a sulfoalkyl-ether-beta-cyclodextrin derivative
KR20160033792A (en) 2007-04-27 2016-03-28 사이덱스 파마슈티칼스, 인크. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
CN106038481A (en) * 2007-06-28 2016-10-26 锡德克斯药物公司 Nasal and ophthalmic delivery of aqueous corticosteroid solutions
CL2008002966A1 (en) 2007-10-04 2010-06-25 Onyx Therapeutics Inc Crystalline keto epoxide tetrapeptide compound; crystalline citrate salt of the compound; methods of preparation; crystalline intermediate compound; Preparation method; and use to treat cancer, autoimmune disease, transplant-related condition, neurodegenerative disease, condition associated with fibrosis, among others.
US20090149432A1 (en) * 2007-11-09 2009-06-11 Shrewsbury Stephen B Methods for administering corticosteroid formulations
EA035100B1 (en) 2008-10-21 2020-04-28 Оникс Терапьютикс, Инк. Combination therapy with peptide epoxyketones
WO2010053487A1 (en) 2008-11-07 2010-05-14 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
US20100196483A1 (en) * 2009-02-04 2010-08-05 Activaero Gmbh Research & Development Method for treatmentof severe and uncontrollable asthma
TWI504598B (en) 2009-03-20 2015-10-21 Onyx Therapeutics Inc Crystalline tripeptide epoxy ketone protease inhibitors
US8236782B2 (en) 2009-05-13 2012-08-07 Cydex Pharmaceuticals, Inc. Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
US9463161B2 (en) * 2009-05-29 2016-10-11 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems
KR101792696B1 (en) 2009-06-18 2017-11-02 알레간 인코포레이티드 Safe desmopressin administration
WO2011060179A1 (en) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
US9359398B2 (en) 2010-03-01 2016-06-07 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
RU2445119C2 (en) * 2010-05-25 2012-03-20 Сергей Викторович Чепур Pharmaceutical composition and method for pulmonary administration thereof
WO2012146642A1 (en) * 2011-04-26 2012-11-01 Activaero Gmbh Administration of iloprost as aerosol bolus
CN102188371B (en) * 2011-05-11 2013-01-23 台州职业技术学院 Ciclesonide nanoparticle aqueous solution and preparation method thereof
CN102973574A (en) * 2011-09-02 2013-03-20 北京燕锋晨医药技术发展有限公司 Pharmaceutical composition for treating asthma and preparation method thereof
EP2847207B1 (en) 2012-05-08 2019-03-27 Nicox Ophthalmics, Inc. Fluticasone propionate nanocrystals
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
EP2662094B1 (en) * 2012-05-08 2024-04-17 Onyx Therapeutics, Inc. Cylodextrin Complexation Methods for Formulating Peptide Proteasome Inhibitors
RU2504382C1 (en) * 2012-06-13 2014-01-20 Шолекс Девелопмент Гмбх Inhalation preparation for treating bronchail asthma and chronic obstructive pulmonary disease and method for preparing it
UY34897A (en) 2012-07-09 2014-01-31 Onyx Therapeutics Inc PROFESSIONALS OF PEPTIDIC INHIBITORS OF EXPOXI CETONA PROTEASA
RU2506080C1 (en) * 2012-09-25 2014-02-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО НижГМА Минздравсоцразвития России) Method for treatment and prevention of oral complications caused by hormonal preparation inhalations in patients suffering bronchial asthma
RU2493827C1 (en) * 2012-10-03 2013-09-27 Шолекс Девелопмент Гмбх Stable combined solution of fenoterol hydrobromide and ipratropium bromide
BR112015010601B1 (en) * 2012-11-09 2022-07-19 Civitas Therapeutics, Inc. PHARMACEUTICAL COMPOSITION AND USE OF THE COMPOSITION
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
KR102391676B1 (en) * 2014-03-28 2022-04-28 유니버시떼 드 리에즈 Composition comprising cyclodextrin and budesonide derivatives for the treatment and prophylaxis of pulmonary inflammations
EP2923702A1 (en) * 2014-03-28 2015-09-30 Universite De Liege Composition of cyclodextrin with budesonide derivatives for treatment and prevention of pulmonary inflammatory disease
WO2016131051A1 (en) * 2015-02-13 2016-08-18 Vanderbilt University Milrinone composition and method for administering same
MA45276A (en) * 2015-06-18 2018-04-25 Sage Therapeutics Inc NEUROACTIVE STEROID SOLUTIONS AND THEIR METHODS OF USE
WO2017193110A1 (en) * 2016-05-06 2017-11-09 Stites Adam Cannabinoid compositions for sublingual spray nebulizer
CR20180594A (en) 2016-06-02 2019-07-29 Abbvie Inc GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF
RU2020117698A (en) 2017-12-01 2022-01-04 Эббви Инк. GLUCOCORTICOID RECEPTOR AGONIST AND ITS IMMUNOCONJUGATES
WO2019147154A1 (en) * 2018-01-23 2019-08-01 Александр Григорьевич ЧУЧАЛИН Pharmaceutical formulation (embodiments) and use of a pharmaceutical formulation (embodiments)
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation
WO2021262675A1 (en) * 2020-06-23 2021-12-30 Anovent Pharmaceutical (U.S.), Llc Preparation of a pharmaceutical composition of olodaterol, tiotropium bromide and budesonide
CN113018280A (en) * 2021-03-01 2021-06-25 石家庄四药有限公司 Solution preparation for ipratropium bromide inhalation and preparation method thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3008875A (en) * 1960-01-08 1961-11-14 Upjohn Co Neomycin and mirystyl-gamma-picolinium halide compositions
BE629985A (en) * 1962-11-29
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (en) * 1990-01-23 1999-01-15 . Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5324718A (en) 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5977070A (en) 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
US5510339A (en) 1993-02-02 1996-04-23 Mayo Foundation For Medical Education And Research Method for the treatment of bronchial asthma by administration of topical anesthetics
NZ263084A (en) 1993-03-12 1997-08-22 Arris Pharm Corp Dipeptide derivatives, treatment of immunomediated inflammatory disorders
BE1007402A5 (en) 1993-03-26 1995-06-06 Adir NASAL PHARMACEUTICAL PREPARATIONS WITH progestagen SUBSTANCE.
ATE241984T1 (en) 1993-03-26 2003-06-15 Franciscus Wilhelmus He Merkus PHARMACEUTICAL COMPOSITIONS FOR INTRANASAL ADMINISTRATION OF APOMORPHINE
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
DK0806945T3 (en) 1994-12-22 2003-08-04 Astrazeneca Ab Therapeutic inhalation preparation containing parathyroid hormone, PTH
DE4446891A1 (en) 1994-12-27 1996-07-04 Falk Pharma Gmbh Stable aqueous budesonide solution
US5840713A (en) * 1995-04-03 1998-11-24 Weisz; Paul B. Therapy for tissue membrane insufficiency
US5576645A (en) * 1995-06-05 1996-11-19 Hughes Aircraft Company Sample and hold flip-flop for CMOS logic
US5668110A (en) 1995-06-07 1997-09-16 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5677280A (en) 1995-06-07 1997-10-14 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5683983A (en) 1995-06-07 1997-11-04 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5654276A (en) 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5750549A (en) 1996-10-15 1998-05-12 Merck & Co., Inc. Cycloalkyl tachykinin receptor antagonists
GB9625843D0 (en) 1996-12-12 1997-01-29 Merck & Co Inc Phenyl spiroethercycloalkyl tachykinn receptor antagonists
US5929094A (en) 1996-10-25 1999-07-27 Merck & Co., Inc. Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists
WO1998018827A1 (en) * 1996-10-28 1998-05-07 Farmarc Nederland B.V. Inclusion complexes of beta-2-andrenergics for oral mucosal delivery
US6071910A (en) 1996-12-05 2000-06-06 Mayo Foundation For Medical Education And Research Use of agents to treat eosinophil-associated pathologies
US5837713A (en) 1997-02-26 1998-11-17 Mayo Foundation For Medical Education And Research Treatment of eosinophil-associated pathologies by administration of topical anesthetics and glucocorticoids
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
DK0889056T3 (en) 1997-07-01 2006-07-17 Pfizer Prod Inc Process for making a cyclodextrin
US20020010197A1 (en) 1998-01-13 2002-01-24 John Dixon Pharmaceutical compositions comprising a compound having dopamine (d2) receptor agonist activity and a compound (b) having beta2-adrenoreceptor agonist activity
EP1067942A1 (en) 1998-02-23 2001-01-17 Cyclops, EHF. High-energy cyclodextrin complexes
US6241969B1 (en) 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US6509323B1 (en) 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
US20020198174A1 (en) * 2001-05-07 2002-12-26 Allergan Sales, Inc. Disinfecting and solubilizing steroid compositions
EP1109581A1 (en) * 1998-09-02 2001-06-27 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
WO2000047203A1 (en) 1999-02-12 2000-08-17 Mqs, Inc. Formulation and system for intra-oral delivery of pharmaceutical agents
FR2789685B1 (en) 1999-02-15 2001-05-04 Univ Lille Sciences Tech PROCESS FOR MANUFACTURING SOLUBLE AND INSOLUBLE POLYMERS BASED ON CYCLODEXTRIN (S) AND / OR DERIVATIVES OF CYCLODEXTRIN (S) AND SOLUBLE POLYMERS BASED ON CYCLODEXTRIN (S) AND / OR DERIVATIVES OF CYCLODEXTRIN (S)
US6136603A (en) 1999-03-26 2000-10-24 Isis Pharmaceuticals Inc. Antisense modulation of interleukin-5 signal transduction
AU775565B2 (en) 1999-10-29 2004-08-05 Novartis Ag Dry powder compositions having improved dispersivity
US6479467B1 (en) 1999-12-16 2002-11-12 Eastman Chemical Company Cyclodextrin ethers
RU2180217C2 (en) 2000-03-21 2002-03-10 Закрытое акционерное общество "Пульмомед" Stable budesonide-containing aqueous solution with anti-inflammatory effect
DE60117777T2 (en) 2000-05-11 2006-08-17 Eastman Chemical Co., Kingsport ACYLATED CYCLODEXTRINE GUEST INCLUSION COMPLEX
AU2002241823A1 (en) 2001-01-11 2002-07-24 Eastman Chemical Company Cyclodextrin sulfonates, guest inclusion complexes, methods of making the same and related materials
JP4313041B2 (en) 2001-02-14 2009-08-12 ナームローゼ・フエンノートチヤツプ・オルガノン 2-alkylated-cyclodextrin derivatives: antagonists to drug-induced neuromuscular blockade
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
CA2501132A1 (en) 2002-10-09 2004-04-22 Insert Therapeutics, Inc. Cyclodextrin-based materials, compositions and uses related thereto

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2591804C2 (en) * 2009-02-25 2016-07-20 Супратек Фарма, Инк. Compositions of bendamustine and cyclopolysaccharide

Also Published As

Publication number Publication date
MX348041B (en) 2017-05-25
DK1732512T3 (en) 2017-07-10
MXPA06007581A (en) 2007-03-09
JP2007517069A (en) 2007-06-28
KR20070007076A (en) 2007-01-12
JP2012224648A (en) 2012-11-15
IL176575A0 (en) 2006-10-31
BRPI0418276A (en) 2007-05-02
CA2551749C (en) 2014-02-11
EP1732512B1 (en) 2017-03-22
EP1732512A4 (en) 2008-07-23
AU2004311478A1 (en) 2005-07-21
RU2390330C2 (en) 2010-05-27
JP2016172774A (en) 2016-09-29
BRPI0418232A (en) 2007-04-27
WO2005065435A3 (en) 2005-09-01
RU2388462C2 (en) 2010-05-10
NZ548225A (en) 2012-12-21
HUE032527T2 (en) 2017-09-28
BRPI0418386A (en) 2007-05-22
RU2006127432A (en) 2008-02-10
WO2005065435A2 (en) 2005-07-21
IL251496B (en) 2021-04-29
EP1732512A2 (en) 2006-12-20
WO2005065649A1 (en) 2005-07-21
JP6186478B2 (en) 2017-08-23
IL225946A0 (en) 2013-06-27
CA2552641A1 (en) 2005-07-21
CN1976679B (en) 2011-08-31
KR20070005586A (en) 2007-01-10
EP1718276A2 (en) 2006-11-08
IL225946A (en) 2017-04-30
PT1732512T (en) 2017-07-24
AU2004312096A1 (en) 2005-07-21
EP1718276A4 (en) 2008-07-23
RU2006127443A (en) 2008-02-10
CN1921830A (en) 2007-02-28
EP1729724A1 (en) 2006-12-13
IL176576A0 (en) 2006-10-31
IL251496A0 (en) 2017-05-29
WO2005065651A1 (en) 2005-07-21
BRPI0418276B8 (en) 2021-05-25
CA2551749A1 (en) 2005-07-21
IL176577A0 (en) 2006-10-31
JP2007517068A (en) 2007-06-28
AU2004312095A1 (en) 2005-07-21
BRPI0418276B1 (en) 2017-02-14
EP3238708A1 (en) 2017-11-01
EP1729724A4 (en) 2008-07-23
CN1976679A (en) 2007-06-06
CN1921834A (en) 2007-02-28
CA2551826A1 (en) 2005-07-21
KR20070007075A (en) 2007-01-12
JP2015129173A (en) 2015-07-16
JP2007517067A (en) 2007-06-28
JP5782413B2 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
RU2006127467A (en) INHALATION PREPARATION FORM CONTAINING SIMPLE SULFALKYL ETHER-CYCLODEXTRIN AND CORTICOSTEROID
JP2007517069A5 (en)
JP2007517067A5 (en)
JP2007517068A5 (en)
JP6214925B2 (en) Formoterol-containing aerosol composition for delivery to the lung via nebulization
US7473710B2 (en) Bronchodilating beta-agonist compositions and methods
US9597396B2 (en) Formoterol/steroid bronchodilating compositions and methods of use thereof
AU2002250199A1 (en) Formoterol/steroid bronchodilating compositions and methods of use thereof
AU2002244211A1 (en) Aerosol Compositions Containing Formoterol for Delivery to the Lungs via Nebulization

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner